February 10, 2020
Summit Pharmaceuticals International Corporation

Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd.
Possessing the Nucleic Acid Pharmaceutical Element Technologies

Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President& CEO: Kenichi Nakamura) (“SPI”) has invested in Luxna Biotech Co., Ltd. (Head Office: Suita City, Osaka,President & CEO: Hideaki Sato) (“Luxna Biotech”), which possesses the nucleic acid pharmaceutical element
technologies and develops novel oligonucleotide therapeutics with high safety and efficacy.
Luxna Biotech develops novel oligonucleotide therapeutics with high safety and efficacy and aims to respondto unmet medical needs for patients who are suffering from diseases and people supporting them, based on thenucleic acid pharmaceutical element technologies accumulated in Osaka University. This time, Luxna Biotech
has completed a third-party allocation of JPY 650 million ("Fundraising") in series A round, and SPI has invested
in Luxna Biotech with Nissan Chemical Corporation (Head Office: Nihonbashi, Chuo-ku, Tokyo, CEO: KojiroKinoshita), Mizuho Capital Co., Ltd. (Head Office: Uchisaiwai-cho, Chiyoda-ku, Tokyo, CEO: Yusuke Omachi)
and Senshu Ikeda Capital Co., Ltd. (Head Office: Chaya-machi, Kita-ku, Osaka, CEO: Katsumi Hiramatsu), inaddition to Osaka University Venture Capital Co., Ltd. (Head Office: Suita City, Osaka, Representative Director:Toshiaki Jimbo) which has been a lead investor since Luxna Biotech’s start-up operation. Luxna Biotech will
use this capital to drive collaboration with pharmaceutical companies and academia by strengthening its
platform technologies for oligonucleotide therapeutics.
SPI is a provider of high-quality integrated products and services to pharmaceutical industry, from researchequipment and bioresources for drug discovery, pharmaceutical licensing and research alliance support, tomanufacturing of APIs, intermediates for pharmaceuticals, generic drugs and biologics. SPI is the provider ofbiological materials of ATCC, the world biggest company of gene/cell bank for researches based in the U.S. SPI
is 100% owned subsidiary company of Sumitomo Corporation which is one of the leading global trading
company with 113 locations in 66 countries and 22 locations in Japan (as of September 30, 2019) with diverse
range of products and services and plays a central role in the medical science business line as a group companyof Sumitomo Corporation. In the field of the nucleic acid therapeutics, SPI has been an agent of BioSpring
GmbH, a German contract manufacturer of oligonucleotides, for Japan since 2010. SPI has good track records
in this field and has accumulated various experiences and know-how. SPI has already established a business
partnership with Luxana Biotech, but this investment will further strengthen this relationship. Utilizing SPI’s
global network, experience, etc., SPI aims to accelerate business in the nucleic acid therapeutics field.

About Luxna Biotech Co., Ltd.
Headquarters and Research Institute: 2-8 Yamadaoka, Suita City, Osaka
Representative: Hideaki Sato

Founded: December 2017
Website: https://luxnabiotech.co.jp/en/

Contact Info
Summit Pharmaceuticals International Corporation
Tel: +81-3-5220-1560

Mail: alliance@summitpharma.co.jp

EOD